SYS6041 not checked

CSPC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SYS6041: RP2D dose, ivgtt, Q3W Enlonstobart:360mg, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W”In the company’s words, NCT07714668 on ClinicalTrials.gov
Tested for
Ovarian Cancer, Recurrent Ovarian Cancer, Advanced Solid Tumors
Main trialPhase 2
“This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.”In the company’s words, NCT07714668 on ClinicalTrials.gov

Other drugs for Ovarian Cancer

All 265 drugs for Ovarian Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Apr 2028 A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
Phase 1/2Recruiting 28 Mar 2027 A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SYS6041

Following is part of Solo: you see every change to SYS6041 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in